cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2019-4-129-136cardiovascular-2334Research ArticleЗАРУБЕЖНАЯ ИНФОРМАЦИЯINTERNATIONAL INFORMATIONСТАТЬЯ ОТОЗВАНА Конгресс Американского Колледжа Кардиологов (Новый Орлеан, 2019): результаты клинических исследованийRETRACTED Congress of the American College of Cardiology (New Orleans, 2019): Clinical Findingshttps://orcid.org/0000-0003-1510-9204КанорскийС. Г.KanorskyS. G.

Канорский Сергей Григорьевич — доктор медицинских наук, профессор, заведующий кафедрой терапии № 2 ФПК и ППС.

Краснодар.

Тел.: +7 (918) 355-82-81

kanorskysg@mail.ruhttps://orcid.org/0000-0001-7131-8049МамедовМ. Н. оглыMamedovM. N.

Мамедов Мехман Ниязи оглы — доктор медицинских наук, профессор, руководитель лаборатории междисциплинарного подхода профилактики ХНИЗ.

Москва.

mmamedov@mail.ruhttps://orcid.org/0000-0003-0875-0773ОгановР. Г.OganovR. G.

Оганов Рафаэль Гегамович— почетный Президент РКО, академик РАН, профессор, главный научный сотрудник, руководитель отдела профилактики коморбидных состояний, НМИЦ профилактической медицины Минздрава России, председатель экспертной группы по неинфекционным заболеваниям ПСИЗСБ.

Москва.

oganov@gnicpm.ruКубанский государственный медицинский университет Минздрава РоссииKuban State Medical UniversityНациональный медицинский исследовательский центр профилактической медицины Минздрава РоссииNational Medical Research Center for Preventive Medicine201904092019184129136Copyright © Канорский С.Г., Мамедов М.Н., Оганов Р.Г., 20192019Канорский С.Г., Мамедов М.Н., Оганов Р.Г.Kanorsky S.G., Mamedov M.N., Oganov R.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2334

Обзорная статья содержит отчет о 18 важнейших клинических исследованиях, представлявшихся на научных сессиях Американского колледжа кардиологов, проходивших в Новом Орлеане (США) 16-18 марта 2019 года.

The review article presents a report on 18 most important clinical trials presented at the scientific sessions of the American College of Cardiology, held in New Orleans (USA) on March 16-18, 2019.

кардиологиясердечно-сосудистые заболеванияклинические исследованияcardiologycardiovascular diseasesclinical trialsReferencesArnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Mar 17. [Epub ahead of print] doi:10.1016/j.jacc.2019.03.010.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Mar 17. [Epub ahead of print] doi:10.1016/j.jacc.2019.03.010.Le May M. R. The SAfety and Efficacy of Femoral Access vs. RadIal Access in ST-Elevation Myocardial Infarction (SAFARI-STEMI) trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019. https://www.acc.org (23 August 2019).Le May M. R. The SAfety and Efficacy of Femoral Access vs. RadIal Access in ST-Elevation Myocardial Infarction (SAFARI-STEMI) trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019. https://www.acc.org (23 August 2019).Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2018;3(5):391-9. doi:10.1001/jamacardio.2018.0612.Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2018;3(5):391-9. doi:10.1001/jamacardio.2018.0612.Berwanger O, Lopes RD, Moia DDF, et al. Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial. J Am Coll Cardiol. 2019;73(22):2819-28. doi:10.1016/j.jacc.2019.03.011.Berwanger O, Lopes RD, Moia DDF, et al. Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial. J Am Coll Cardiol. 2019;73(22):2819-28. doi:10.1016/j.jacc.2019.03.011.Kronish I. M. Randomized trial of depression screening after acute coronary syndromes results from Comparison of Depression Identification After Acute Coronary Syndromes-Quality of Life and Cost Effectiveness (CODIACS-QoL). Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 16, 2019. https://www.acc.org (23 August 2019).Kronish I. M. Randomized trial of depression screening after acute coronary syndromes results from Comparison of Depression Identification After Acute Coronary Syndromes-Quality of Life and Cost Effectiveness (CODIACS-QoL). Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 16, 2019. https://www.acc.org (23 August 2019).Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261- 74. doi:101001/jama.2019.0693.Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261- 74. doi:101001/jama.2019.0693.Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275-85. doi:10.1001/jama.2019.0692.Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275-85. doi:10.1001/jama.2019.0692.Voskoboinik A. Impact of Alcohol Abstinence in Moderate Drinkers with Atrial Fibrillation: Results from the Alcohol-AF Randomized Controlled Trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019. https://www.acc.org (23 August 2019).Voskoboinik A. Impact of Alcohol Abstinence in Moderate Drinkers with Atrial Fibrillation: Results from the Alcohol-AF Randomized Controlled Trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019. https://www.acc.org (23 August 2019).Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. N Engl J Med. 2019;380(15):1397-407. doi:10.1056/NEJMoa1816897.Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. N Engl J Med. 2019;380(15):1397-407. doi:10.1056/NEJMoa1816897.Turakhia M. The Apple Heart Study: Results of a Large-scale, App-based Study To Identify Atrial Fibrillation Using A Smartwatch. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 16, 2019. https://www.acc.org (23 August 2019).Turakhia M. The Apple Heart Study: Results of a Large-scale, App-based Study To Identify Atrial Fibrillation Using A Smartwatch. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 16, 2019. https://www.acc.org (23 August 2019).Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509-24. doi:10.1056/NEJMoa1817083.Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509-24. doi:10.1056/NEJMoa1817083.Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321(24):2414-27. doi:10.1001/jama.2019.8145.Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321(24):2414-27. doi:10.1001/jama.2019.8145.Hahn J-Y, Song YB, Oh JH, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321(24):2428-37. doi:10.1001/jama.2019.8146.Hahn J-Y, Song YB, Oh JH, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321(24):2428-37. doi:10.1001/jama.2019.8146.Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med. 2019;380(19):1825-33. doi:10.1056/NEJMoa1901778.Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med. 2019;380(19):1825-33. doi:10.1056/NEJMoa1901778.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695- 705. doi:10.1056/NEJMoa1814052.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695- 705. doi:10.1056/NEJMoa1814052.Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-15. doi:10.1056/NEJMoa1816885.Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-15. doi:10.1056/NEJMoa1816885.Arnold SV, Chinnakondepalli KM, Spertus JA, et al. Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. J Am Coll Cardiol. 2019;73(17):2123-32. doi:10.1016/j.jacc.2019.02.010.Arnold SV, Chinnakondepalli KM, Spertus JA, et al. Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. J Am Coll Cardiol. 2019;73(17):2123-32. doi:10.1016/j.jacc.2019.02.010.Rollman B. Blended Collaborative Care for Treating Heart Failure and Comorbid Depression. 12-Month Primary Outcomes from the Hopeful Heart Trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 16, 2019. https://www.acc.org (23 August 2019).Rollman B. Blended Collaborative Care for Treating Heart Failure and Comorbid Depression. 12-Month Primary Outcomes from the Hopeful Heart Trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 16, 2019. https://www.acc.org (23 August 2019).Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019;380(17):1618-27 doi:10.1056/NEJMoa1900486.Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019;380(17):1618-27 doi:10.1056/NEJMoa1900486.Azizi M, Schmieder RE, Mahfoud F, et al. Six-Month Results of Treatment- Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE- HTN SOLO Trial. Circulation. 2019 Mar 17. [Epub ahead of print] doi: 10.1161/CIRCULATIONAHA.119.040451.Azizi M, Schmieder RE, Mahfoud F, et al. Six-Month Results of Treatment- Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE- HTN SOLO Trial. Circulation. 2019 Mar 17. [Epub ahead of print] doi: 10.1161/CIRCULATIONAHA.119.040451.White W. B. Primary Results of the Intensive versus Standard Ambulatory Blood Pressure Lowering to Lessen Functional Decline in the Elderly Trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019. https://www.acc.org (23 August 2019).White W. B. Primary Results of the Intensive versus Standard Ambulatory Blood Pressure Lowering to Lessen Functional Decline in the Elderly Trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019. https://www.acc.org (23 August 2019).

The authors declare that there are no conflicts of interest present.